CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
降低毒性的 CAR-T 细胞工程策略
英文原题：CAR T cell engineering approaches to minimise toxicities.
查看英文原题
CAR T cell engineering approaches to minimise toxicities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
对于多种癌症的治疗，基于细胞和基因的疗法在临床前数据和临床试验中都显示出前景。特别是CAR-T 细胞疗法，目前已有7种FDA批准的产品，在血液系统癌症如多发性骨髓瘤和B细胞恶性肿瘤中显示出突破性结果。最近的研究还试图开发针对实体瘤的有效CAR-T 细胞疗法，但成功程度不一。CAR-T 细胞疗法面临的关键挑战之一是在强效细胞毒性活性以实现有效治疗与预防严重且可能致命的毒性（如细胞因子释放综合征和免疫效应细胞相关神经毒性综合征）之间取得平衡。这篇小型综述讨论了科学家为克服毒性并改进现有CAR-T 细胞疗法而设计的一些潜在解决方案。
展开英文摘要原文
For the treatment of many forms of cancer, cell- and gene-based therapies are showing promise in both pre-clinical data and clinical trials. In particular, CAR T cell therapies, of which there are now 7 FDA-approved products, have shown ground-breaking results in haematological cancers such as multiple myeloma and B cell malignancies. Recent research is also attempting to develop effective CAR T cell therapies for solid tumours, with varying success.
One of the key challenges faced by CAR T cell therapy is balancing strong cytotoxic activity for an effective treatment with preventing severe and potentially lethal toxicities, such as Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome. This mini review discusses some of the potential solutions that scientists have devised to overcome toxicities and improve existing CAR T cell therapies.
论文信息
- 作者
- Hogben E、Schurich A、Graham C
- 单位
- Department of Haematology, King's College London, London, United Kingdom.United Kingdom
- 文献类型
- 综述
- 期刊
- Experimental biology and medicine (Maywood, N.J.)2026
- 原文标识
- PubMed 42063678 · DOI 10.3389/ebm.2026.11021
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →